Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer
复制标题
DOI：
10.1038/sj.bjc.6601195
复制
发表时间：
2003-09-15
影响因子：
8.8
通讯作者：
Foulkes, WD
中科院分区：
文献类型：
--
作者：
Goffin, JR;Straume, O;Foulkes, WD
乳腺癌的肾小球微血管增生（GMP）单独对生存产生不利影响（相对危险度为1.9,95% CI: 1.2 - 3.0），尤其是接受辅助化疗的女性（10年生存率为27 vs 69%， P = 0.0003），并且与p53过表达和BRCA1种系突变显著相关。GMP的存在可能影响治疗决策。
Glomeruloid microvascular proliferation (GMP) in breast cancer independently adversely affected survival ( relative risk 1.9, 95% CI: 1.2 - 3.0), particularly among women who received adjuvant chemotherapy ( 10-year survival 27 vs 69%, P = 0.0003), and was significantly associated with p53 overexpression and BRCA1 germline mutations. The presence of GMP may influence treatment decisions.